Procalcitonin Level and Kinetics in Children With Bacterial Infections
Sponsor
Shaare Zedek Medical Center (Other)
Overall Status
Completed
CT.gov ID
NCT00714402
Collaborator
(none)
50
1
Study Details
Study Description
Brief Summary
The purposes of this study are:
-
To determine whether procalcitonin level at admission of pediatric patients with bacterial infections can be used as a marker for prediction of defervescence and hospitalization length
-
To examine the kinetics of procalcitonin in pediatric patients with bacterial infections and persistent fever
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
|
Study Design
Study Type:
Observational
Anticipated Enrollment
:
50 participants
Observational Model:
Case-Only
Time Perspective:
Prospective
Official Title:
Procalcitonin Level as a Prognostic Marker and Its' Kinetics in Children With Bacterial Infections
Study Start Date
:
Aug 1, 2008
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| a children with proven of probable invasive bacterial infections |
Outcome Measures
Primary Outcome Measures
- time to defervescence [discharge]
Secondary Outcome Measures
- length of hospitalization [discharge]
Eligibility Criteria
Criteria
Ages Eligible for Study:
3 Days
to 16 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
-
Positive blood, urine, synovial, bone, pleural effusion, abscess or CSF culture
-
Cellulitis, lobar pneumonia, osteomyelitis,
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Shaare Zedek Medical Center | Jerusalem | Pob 3235 | Israel | 91031 |
Sponsors and Collaborators
- Shaare Zedek Medical Center
Investigators
- Principal Investigator: Yechiel Schlesinger, MD, Shaare Zedek Medical Center
Study Documents (Full-Text)
None provided.More Information
Publications
- Assicot M, Gendrel D, Carsin H, Raymond J, Guilbaud J, Bohuon C. High serum procalcitonin concentrations in patients with sepsis and infection. Lancet. 1993 Feb 27;341(8844):515-8.
- Boussekey N, Leroy O, Alfandari S, Devos P, Georges H, Guery B. Procalcitonin kinetics in the prognosis of severe community-acquired pneumonia. Intensive Care Med. 2006 Mar;32(3):469-72. Epub 2006 Feb 14.
- Christ-Crain M, Stolz D, Bingisser R, Müller C, Miedinger D, Huber PR, Zimmerli W, Harbarth S, Tamm M, Müller B. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med. 2006 Jul 1;174(1):84-93. Epub 2006 Apr 7.
- Hatherill M, Tibby SM, Turner C, Ratnavel N, Murdoch IA. Procalcitonin and cytokine levels: relationship to organ failure and mortality in pediatric septic shock. Crit Care Med. 2000 Jul;28(7):2591-4.
- Le Moullec JM, Jullienne A, Chenais J, Lasmoles F, Guliana JM, Milhaud G, Moukhtar MS. The complete sequence of human preprocalcitonin. FEBS Lett. 1984 Feb 13;167(1):93-7.
- Nobre V, Harbarth S, Graf JD, Rohner P, Pugin J. Use of procalcitonin to shorten antibiotic treatment duration in septic patients: a randomized trial. Am J Respir Crit Care Med. 2008 Mar 1;177(5):498-505. Epub 2007 Dec 20.
- Schuetz P, Christ-Crain M, Wolbers M, Schild U, Thomann R, Falconnier C, Widmer I, Neidert S, Blum CA, Schönenberger R, Henzen C, Bregenzer T, Hoess C, Krause M, Bucher HC, Zimmerli W, Müller B; ProHOSP study group. Procalcitonin guided antibiotic therapy and hospitalization in patients with lower respiratory tract infections: a prospective, multicenter, randomized controlled trial. BMC Health Serv Res. 2007 Jul 5;7:102.
- Seligman R, Meisner M, Lisboa TC, Hertz FT, Filippin TB, Fachel JM, Teixeira PJ. Decreases in procalcitonin and C-reactive protein are strong predictors of survival in ventilator-associated pneumonia. Crit Care. 2006;10(5):R125.
Responsible Party:
,
,
ClinicalTrials.gov Identifier:
NCT00714402
Other Study ID Numbers:
- pct.ctil
First Posted:
Jul 14, 2008
Last Update Posted:
May 18, 2011
Last Verified:
Jan 1, 2009
Keywords provided by ,
,
Additional relevant MeSH terms: